NVCT Stock Overview
A biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Nuvectis Pharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.67 |
52 Week High | US$18.65 |
52 Week Low | US$5.85 |
Beta | 0.44 |
1 Month Change | -6.06% |
3 Month Change | -10.59% |
1 Year Change | -61.33% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 105.23% |
Recent News & Updates
Recent updates
Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?
Jan 06Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation
Oct 03We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
Jan 31Nuvectis Pharma forms scientific advisory board for research and development of drugs
Sep 28Nuvectis Pharma GAAP EPS of -$0.28 misses by $0.04
Aug 05Nuvectis Pharma declines 13%, announces $15.9M private placement
Jul 27We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
May 04Shareholder Returns
NVCT | US Biotechs | US Market | |
---|---|---|---|
7D | 0.3% | 0.7% | 1.2% |
1Y | -61.3% | 5.0% | 27.7% |
Return vs Industry: NVCT underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: NVCT underperformed the US Market which returned 27.7% over the past year.
Price Volatility
NVCT volatility | |
---|---|
NVCT Average Weekly Movement | 14.9% |
Biotechs Industry Average Movement | 11.2% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.2% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NVCT's share price has been volatile over the past 3 months.
Volatility Over Time: NVCT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 13 | Ron Bentsur | www.nuvectis.com |
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company’s lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases.
Nuvectis Pharma, Inc. Fundamentals Summary
NVCT fundamental statistics | |
---|---|
Market cap | US$111.60m |
Earnings (TTM) | -US$22.38m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.5x
P/E RatioIs NVCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NVCT income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$22.38m |
Earnings | -US$22.38m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.22 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did NVCT perform over the long term?
See historical performance and comparison